Milestone Scientific Inc., a developer of computerized drug delivery instruments that provide painless and precise injections, announced Sept. 22 the appointment of Dr. Dawood Sayed, a nationally recognized leader in interventional pain medicine, to its board of directors, effective immediately.
Sayed is a professor of anesthesiology and pain medicine at the University of Kansas Medical Center and serves as division chief of pain medicine, director of interventional spine services, and director of the center for neuromodulation. He brings over a decade of leadership in pioneering minimally invasive pain therapies, neuromodulation, and health system innovation.
Sayed also serves as vice chairman and co-founder of the American Society of Pain and Neuroscience, where he works with stakeholders, including commercial payers, regulators, and medical device manufacturers to advance access to innovative pain relief technologies. Among his recognitions are the 2025 Presidential Award from the North American Neuromodulation Society.
“Dr. Sayed’s appointment is a significant step forward in our commitment to build a clinically informed, market-driven organization,” said Eric Hines, chief executive officer of Milestone Scientific. “As we move into the next phase of commercial growth, his knowledge of health system adoption, clinical training, and reimbursement strategy will help accelerate our penetration into the interventional pain management space.”
“I am excited to join Milestone Scientific’s Board at a time when innovation in interventional pain care is critical to improving patient outcomes and reducing opioid reliance,” said Dr. Sayed. “CompuFlo is a truly disruptive technology that addresses a long-standing challenge in spinal procedures. I look forward to working with the team to drive greater clinical adoption and improve procedural safety.”
